Tony Berberabe, MPH

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

“We have seen a number of dynamic changes in MDS over the last few years, and integrating them into our treatment paradigm will impact our approach, and perhaps offer a glimpse into the future."

An expert addressed the emerging role of immune checkpoint inhibitors in the perioperative space based on findings from the CheckMate 816, IMpower010, PEARLS, and ADAURA trials.

In the mHSPC setting, treatment approaches are rapidly evolving, sparking ongoing debate among clinicians about the efficacy of doublet vs triplet therapy.

A study found that anito-cel is a promising CAR T-cell therapy for relapsed/refractory multiple myeloma with high efficacy and manageable safety.

Camrelizumab increased the 3-year event-free survival rate vs standard of care from 77.3% to 86.9%, translating to a 44% reduced risk of death or relapse in patients with nasopharyngeal carcinoma.

With immunotherapy-based regimens and novel agents like bispecific antibodies and antibody-drug conjugates, oncologist David R. Spigel, MD, is optimistic about the future of small cell lung cancer treatment.

The RAPSON trial found that receiving radium-223 prior to docetaxel in patients with metastatic castration-resistant prostate cancer improved quality of life and tolerability compared to the reverse sequence, without affecting progression-free survival or overall survival.

Longer follow-up from the phase 3 AMBASSADOR trial showed adjuvant pembrolizumab to demonstrate a statistically significant and clinically meaningful improvement in disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma.

Breast cancer diagnostics, therapeutics, and biomarker-driven therapy will be important focal points during the 22nd Annual School of Breast Oncology conference.

While challenges exist in treating peripheral T-cell lymphoma, ongoing research is developing more effective therapies.

Harnessing the power of the immune system has emerged as a key approach in addressing T-cell malignancies, with efforts to leverage the immune system leading to significant improvements beyond the traditional scope of surgery, radiation therapy, and chemotherapy.

Advances in follicular lymphoma treatment have included the development of novel immunotherapies in relapsed and refractory disease and long-term follow-up of pivotal trials.

A number of studies are challenging the current gastrointestinal cancer treatment landscape.

Significant progress has been made since the approval of the first CAR T-cell therapy, but there is still tremendous room for improvement.

An interim analysis of the phase 2 REGINA trial met predefined statistical criteria and suggests the need for further evaluation of the combination of regorafenib, nivolumab, and short-course radiation therapy in patients with locally advanced rectal cancer.

Final analysis from KEYNOTE-585 revealed that event-free survival (EFS) was not significantly improved.

In certain patients, surgical omission, radiotherapy omission, and immunotherapy are being explored.

In general, mutations can occur in several genes in cytologically normal AML cells, including NPM1, FLT3, CEBPA, MLL, NRAS.

Recent data, trials, approvals, and presentations during the 2024 American Urological Association Annual Meeting paint a positive treatment landscape for patients with metastatic and non–muscle-invasive bladder cancer.

The national shortage of nurses and health care support staff has spilled over to the clinical research space.

The standard first-line treatment for patients with HER2-positive metastatic breast cancer is pertuzumab and trastuzumab, which are anti-HER2 antibodies, plus a taxane.

Modified FOLFIRINOX with nivolumab in the neoadjuvant setting was associated with favorable rates of R0 resection in patients with borderline resectable pancreatic cancer.

Encouraging trends were seen with osimertinib and platinum-pemetrexed chemotherapy in patients with EGFR-mutated advanced non–small cell lung cancer in the phase 3 FLAURA2 study.

The combination of the adenovirus CAN-2409 and valacyclovir with continued immune checkpoint inhibitor therapy demonstrated favorable tolerability and induced a positive immune response.

A retrospective study revealed outcomes of sequencing the 2 antibody-drug conjugates trastuzumab deruxtecan and sacituzumab govitecan in patients with metastatic breast cancer.

Trials in small cell lung cancer and non–small cell lung cancer are fueling excitement in the oncology community.

In a phase 1/2 trial of NT219 with cetuximab in patients with squamous cell carcinoma of the head and neck, safety and tolerability responses were encouraging.

Decentralized clinical trials represent a promising approach to clinical research that can improve patient access to new treatments while streamlining the development process.